Literature DB >> 23039309

MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia.

Lorenzo De Paoli, Michaela Cerri, Sara Monti, Silvia Rasi, Valeria Spina, Alessio Bruscaggin, Mariangela Greco, Carmela Ciardullo, Rosella Famà, Stefania Cresta, Rossana Maffei, Marco Ladetto, Maurizio Martini, Luca Laurenti, Francesco Forconi, Roberto Marasca, Luigi M Larocca, Francesco Bertoni, Gianluca Gaidano, Davide Rossi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23039309     DOI： 10.3109/10428194.2012.723706

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  30 in total

Review 1.  An overview of MYC and its interactome.

Authors:  Maralice Conacci-Sorrell; Lisa McFerrin; Robert N Eisenman
Journal:  Cold Spring Harb Perspect Med       Date:  2014-01-01       Impact factor: 6.915

Review 2.  Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis.

Authors:  Daniel Diolaiti; Lisa McFerrin; Patrick A Carroll; Robert N Eisenman
Journal:  Biochim Biophys Acta       Date:  2014-05-22

Review 3.  Richter transformation in the era of novel agents.

Authors:  Wei Ding
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

4.  Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.

Authors:  Franz X Schaub; Varsha Dhankani; Ashton C Berger; Mihir Trivedi; Anne B Richardson; Reid Shaw; Wei Zhao; Xiaoyang Zhang; Andrea Ventura; Yuexin Liu; Donald E Ayer; Peter J Hurlin; Andrew D Cherniack; Robert N Eisenman; Brady Bernard; Carla Grandori
Journal:  Cell Syst       Date:  2018-03-28       Impact factor: 10.304

5.  Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.

Authors:  Monica Messina; Ilaria Del Giudice; Hossein Khiabanian; Davide Rossi; Sabina Chiaretti; Silvia Rasi; Valeria Spina; Antony B Holmes; Marilisa Marinelli; Giulia Fabbri; Alfonso Piciocchi; Francesca R Mauro; Anna Guarini; Gianluca Gaidano; Riccardo Dalla-Favera; Laura Pasqualucci; Raul Rabadan; Robin Foà
Journal:  Blood       Date:  2014-02-18       Impact factor: 22.113

Review 6.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

Review 7.  Treatment of Richter's Syndrome.

Authors:  Adalgisa Condoluci; Davide Rossi
Journal:  Curr Treat Options Oncol       Date:  2017-11-21

8.  Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.

Authors:  Viktor Ljungström; Diego Cortese; Emma Young; Tatjana Pandzic; Larry Mansouri; Karla Plevova; Stavroula Ntoufa; Panagiotis Baliakas; Ruth Clifford; Lesley-Ann Sutton; Stuart J Blakemore; Niki Stavroyianni; Andreas Agathangelidis; Davide Rossi; Martin Höglund; Jana Kotaskova; Gunnar Juliusson; Chrysoula Belessi; Nicholas Chiorazzi; Panagiotis Panagiotidis; Anton W Langerak; Karin E Smedby; David Oscier; Gianluca Gaidano; Anna Schuh; Frederic Davi; Christiane Pott; Jonathan C Strefford; Livio Trentin; Sarka Pospisilova; Paolo Ghia; Kostas Stamatopoulos; Tobias Sjöblom; Richard Rosenquist
Journal:  Blood       Date:  2015-12-16       Impact factor: 22.113

Review 9.  Clinical implications of the molecular genetics of chronic lymphocytic leukemia.

Authors:  Robin Foà; Ilaria Del Giudice; Anna Guarini; Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

10.  Multi-Omics Analysis Identifies MGA as a Negative Regulator of the MYC Pathway in Lung Adenocarcinoma.

Authors:  Paula Llabata; Yoichiro Mitsuishi; Peter S Choi; Diana Cai; Joshua M Francis; Manuel Torres-Diz; Namrata D Udeshi; Lior Golomb; Zhong Wu; Jin Zhou; Tanya Svinkina; Estrella Aguilera-Jimenez; Yanli Liu; Steven A Carr; Montse Sanchez-Cespedes; Matthew Meyerson; Xiaoyang Zhang
Journal:  Mol Cancer Res       Date:  2019-12-20       Impact factor: 5.852
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.